Molecular Biology Reports

, Volume 40, Issue 2, pp 1591–1597

Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment

  • Nur Selvi
  • Burçin Tezcanlı Kaymaz
  • Handan Haydaroğlu Şahin
  • Mustafa Pehlivan
  • Çağdaş Aktan
  • Ayşegül Dalmızrak
  • Ezgi İnalpolat
  • Buket Kosova
  • Mehmet Yılmaz
  • Vahap Okan
  • Güray Saydam
Article

Abstract

The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.

Keywords

Hes Imatinib Real-time PCR FIP1L1-PDGFRA fusion 

References

  1. 1.
    Mannelli L, Cherian V, Nayar A, Srichai-Parsia M (2012) Loeffler’s endocarditis in hypereosinophilic syndrome. Curr Probl Diagn Radiol 41(4):146–148PubMedCrossRefGoogle Scholar
  2. 2.
    Gotlib J (2011) World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 86(8):677–688PubMedCrossRefGoogle Scholar
  3. 3.
    Fujimi A, Kanisawa Y, Kikuchi S, Okuda T, Sato Y, Doi T, Ohta H, Umeda I, Nobuoka A (2007) Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib. Nihon Naika Gakkai Zasshi 96(12):2794–2797PubMedCrossRefGoogle Scholar
  4. 4.
    Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101:3391PubMedCrossRefGoogle Scholar
  5. 5.
    Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101(12):4714–4716PubMedCrossRefGoogle Scholar
  6. 6.
    Weller PF, Bubley GJ (1994) The idiopathic hypereosinophilic syndrome. Blood 83(10):2759–2779PubMedGoogle Scholar
  7. 7.
    Matsuo Y, Inokuma S (2011) Idiopathic hypereosinophilic syndrome (idiopathic HES). Arerugi 60(1):1–8PubMedGoogle Scholar
  8. 8.
    Sheikh J, Weller PF (2009) Advances in diagnosis and treatment of eosinophilia. Curr Opin Hematol 16(1):3–8PubMedCrossRefGoogle Scholar
  9. 9.
    Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101(12):4660–4666PubMedCrossRefGoogle Scholar
  10. 10.
    Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201–1214PubMedCrossRefGoogle Scholar
  11. 11.
    Frigui M, Hmida MB, Jallouli M, Kechaou M, Frikha F, Bahloul Z (2010) Membranous glomerulopathy associated with idiopathic hypereosinophilic syndrome. Saudi J Kidney Dis Transpl 211(2):320–322Google Scholar
  12. 12.
    Choi YJ, Lee JD, Yang KH, Woo JY, Kim BK, Bang BK, Shim SI (1998) Immunotactoid glomerulopathy associated with idiopathic hypereosinophilic syndrome. Am J Nephrol 18(4):337–343PubMedCrossRefGoogle Scholar
  13. 13.
    Giudicelli CP, Didelot F, Duvic C, Desrame J, Herody M, Nedelec G (1998) Eosinophilia and renal pathology. Med Trop (Mars) 58:477–481Google Scholar
  14. 14.
    Garella G, Marra L (1990) Hypereosinophilic syndrome and renal insufficiency. Minerva Urol Nefrol 42(2):135–136PubMedGoogle Scholar
  15. 15.
    Richardson P, Dickinson G, Nash S, Hoffman L, Steingart R, Germain M (1995) Crescentic glomerulonephritis and eosinophilic interstitial infiltrates in a patient with hypereosinophilic syndrome. Postgrad Med J 71(833):175–178PubMedCrossRefGoogle Scholar
  16. 16.
    Hirszel P, Cashell AW, Whelan TV, Dolan R, Yoshihashi A (1998) Urinary Charcot-Leyden crystals in the hypereosinophilic syndrome with acute renal failure. Am J Kidney Dis 12(4):319–322Google Scholar
  17. 17.
    Wojciechowska C, Gala A, Kuczaj A, Jachec W, Foremny A, Helbig G, Wojnicz R, Nowalany-Kozielska E (2011) Heart failure mimicking prior myocardial infarction in a patient with idiopathic hypereosinophilic syndrome. Int Heart J 52(3):194–196PubMedCrossRefGoogle Scholar
  18. 18.
    Ten Oever J, Theunissen LJ, Tick LW, Verbunt RJ (2011) Cardiac involvement in hypereosinophilic syndrome. Neth J Med 69(5):240–244PubMedGoogle Scholar
  19. 19.
    Chen CH, Tsai IC, Jan SL, Tsai WL, Chen CC (2011) MDCT evaluation of cardiac involvement in hypereosinophilic syndrome: differentiating mural thrombus, infarcted, and noninfarcted myocardium by delayed-phase scanning. Tex Heart Inst J 38(2):166–169PubMedGoogle Scholar
  20. 20.
    Cincin AA, Ozben B, Tanrikulu MA, Baskan O, Agirbasli M (2008) Large apical thrombus in a patient with persistent heart failure and hypereosinophilia: Löffler endocarditis. J Gen Intern Med 23(10):1713–1718PubMedCrossRefGoogle Scholar
  21. 21.
    Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M (2004) Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica 89(2):236–237PubMedGoogle Scholar
  22. 22.
    Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109(11):4635–4640PubMedCrossRefGoogle Scholar
  23. 23.
    Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9):1173–1179PubMedCrossRefGoogle Scholar
  24. 24.
    Vigna E, Lucia E, Gentile M, Mazzone C, Bisconte MG, Gentile C, Armentano A, Ottaviani E, Rondoni M, Martinelli G, Morabito F (2008) PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. Cancer Chemother Pharmocol 61(4):713–716CrossRefGoogle Scholar
  25. 25.
    Butterfield JH, Weiter J (2012) Treatment of hypereosinophilic syndromes–the first 100 years. Semin Hematol 49(2):182–191PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Nur Selvi
    • 1
  • Burçin Tezcanlı Kaymaz
    • 1
  • Handan Haydaroğlu Şahin
    • 2
  • Mustafa Pehlivan
    • 2
  • Çağdaş Aktan
    • 1
  • Ayşegül Dalmızrak
    • 1
  • Ezgi İnalpolat
    • 1
  • Buket Kosova
    • 1
  • Mehmet Yılmaz
    • 2
  • Vahap Okan
    • 2
  • Güray Saydam
    • 3
  1. 1.Department of Medical BiologySchool of Medicine, Ege UniversityIzmirTurkey
  2. 2.Department of HematologySchool of Medicine, Gaziantep UniversityGaziantepTurkey
  3. 3.Department of HematologySchool of Medicine, Ege UniversityIzmirTurkey

Personalised recommendations